Guangzheng Eye Hospital Group Co.Ltd(002524)
Securities code: Guangzheng Eye Hospital Group Co.Ltd(002524) securities abbreviation: Guangzheng Eye Hospital Group Co.Ltd(002524) Announcement No.: 2022018 Guangzheng Eye Hospital Group Co.Ltd(002524)
Announcement on the progress of major asset restructuring performance compensation litigation
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Important:
1. The litigation stage of the case: the case has been filed but not heard
2. The party status of the listed company in this progress: the respondent
3. The main litigation request of this lawsuit is to increase the litigation request for the counterclaim proposed in the previous two times. Specifically, it is to increase the litigation request for the counterclaim of the listed company’s acquisition of 51% equity of Shanghai Xinshijie Ophthalmic Hospital Investment Co., Ltd. for the counterclaim that the counterclaim pays the balance of the fifth phase equity transaction price of the restructuring transaction to the counterclaim of RMB Shanghai Pudong Development Bank Co.Ltd(600000) 00, And the loss of overdue payment of equity transaction price, temporarily totaling RMB 176116666. For the counterclaim of the listed company’s acquisition of 49% equity of Shanghai Xinshijie Ophthalmic Hospital Investment Co., Ltd., it is proposed to increase the litigation request. The counterclaim pays the balance of the fourth phase equity transaction price of the restructuring transaction to the counterclaim of RMB 111150000, and the loss of overdue payment of equity transaction price, temporarily totaling RMB 326256125.
Guangzheng Eye Hospital Group Co.Ltd(002524) (hereinafter referred to as ” Guangzheng Eye Hospital Group Co.Ltd(002524) ,” company “or” respondent “) recently received a notice from the second intermediate people’s Court of Shanghai, Lin Chunguang, Shanghai Xinshijie Industry Co., Ltd., Shanghai Nie Hong information consulting partnership (limited partnership) The counterclaim (Announcement No.: 20211112021128) filed by Shanghai Chunhong enterprise management partnership (limited partnership) on the equity transfer dispute related to the compensation for the performance of the company’s major asset restructuring is added. The details are as follows: I. Basic information of the progress of this lawsuit
(I) raise a counterclaim against the listed company’s acquisition of 51% equity of Shanghai Xinshijie Ophthalmic Hospital Investment Co., Ltd
(1) Parties
Counterclaim 1: Lin Chunguang (hereinafter referred to as “counterclaim”)
Male, born on October 16, 1970, Han nationality
Address: No. 1389, Liquan West Avenue, Houjiang village, Dongzhuang Town, Xiuyu District, Putian City, Fujian Province
Counterclaim 2: Shanghai Xinshijie Industrial Co., Ltd. (hereinafter referred to as “the counterclaim”)
Guangzheng Eye Hospital Group Co.Ltd(002524)
Legal representative: Huang Zhanhui
Address: room j3492, No. 500, Xincheng Road, Jiading District, Shanghai
Counterclaim 3: Shanghai Nie Hong information consulting partnership (limited partnership) (hereinafter referred to as “counterclaim”), legal representative: Wu Jinye
Domicile: room 3002, building 5, No. 741, Yaozhou Road, Xincun Township, Chongming District, Shanghai (Shanghai Xincun economic community), counter plaintiff 4: Shanghai Chunhong enterprise management partnership (limited partnership) (hereinafter referred to as “counter plaintiff”), legal representative: Chen Dongdong
Address: room 3000, building 5, No. 741, Yaozhou Road, Xincun Township, Chongming District, Shanghai (Shanghai Xincun economic community), respondent: Guangzheng Eye Hospital Group Co.Ltd(002524)
Legal representative: Zhou Yonglin
Address: No. 266, North Ronghe Road, Urumqi Economic and Technological Development Zone, Xinjiang
(2) Counterclaim’s claim
Apply for adding two original claims, and all counterclaims after adding are as follows:
1. Request that the respondent be ordered to pay the outstanding balance of the fourth equity transaction price of RMB Shanghai Pudong Development Bank Co.Ltd(600000) 00 to the respondent.
2. The counterclaim is requested to order the counterclaim to pay the counterclaim the loss of overdue payment of equity transaction price, temporarily totaling RMB 3272500.
3. Request that the respondent be ordered to pay to the respondent the balance of the equity transaction price of the fifth phase of the restructuring transaction of RMB Shanghai Pudong Development Bank Co.Ltd(600000) 00.
If the defendant fails to pay the transaction price of RMB 176666 yuan, the counterclaim shall pay the counterclaim to the defendant.
5. The litigation costs of this case shall be borne by the respondent.
(II) raise a counterclaim against the listed company’s acquisition of 49% equity of Shanghai Xinshijie Ophthalmic Hospital Investment Co., Ltd
(1) Parties
Counterclaim: Shanghai Xinshijie Industrial Co., Ltd. (hereinafter referred to as “counterclaim”)
Legal representative: Huang Zhanhui
Address: room j3492, No. 500, Xincheng Road, Jiading District, Shanghai
Respondent: Guangzheng Eye Hospital Group Co.Ltd(002524)
Guangzheng Eye Hospital Group Co.Ltd(002524)
Legal representative: Zhou Yonglin
Address: No. 266, North Ronghe Road, Urumqi Economic and Technological Development Zone, Xinjiang
(2) Counterclaim’s claim
Apply for adding two original claims, and all counterclaims after adding are as follows:
1. Request to order the respondent to pay the balance of the third installment of equity transaction price in arrears to the counterclaim of RMB 81650000.
2. The counterclaim is requested to order the counterclaim to pay the loss of overdue payment of equity transaction price to the counterclaim, temporarily amounting to RMB 3143525.
3. The counterclaim paid the counterclaim the balance of the equity transaction price of the fourth phase of the restructuring transaction of RMB 111150000.
4. The counterclaim is requested to order the counterclaim to pay the loss of overdue payment of equity transaction price to the counterclaim, temporarily totaling RMB 326256125.
5. The litigation costs of this case shall be borne by the respondent.
2、 Other litigation and arbitration matters
The company has specifically disclosed the litigation and response matters involved in the current and previous periods in the chapter of litigation matters in the periodic report. If any litigation matters meet the relevant disclosure standards, the company will perform the disclosure obligation in time. 3、 The impact of the lawsuit announced this time on the company’s current profit or post period profit
This lawsuit is based on the counterclaim raised by the company against Xinshijie industry and other defendants on the dispute over performance compensation for major asset restructuring. Since no effective judgment has been formed yet, it is impossible to judge the impact on the current and future profits of the company.
4、 Follow up matters
The company will actively respond to the lawsuit and safeguard the interests of the company and all shareholders according to law. Since this lawsuit has not yet been heard, the result of the lawsuit is uncertain. The company will timely perform the obligation of information disclosure according to the progress of the case. Please pay attention to investment risks.
It is hereby announced.
Guangzheng Eye Hospital Group Co.Ltd(002524) board of directors March 12, 2002
